Trials / Active Not Recruiting
Active Not RecruitingNCT05661955
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-A445 | administered intravenously |
| DRUG | Tislelizumab | administered intravenously |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2025-05-27
- Completion
- 2026-10-01
- First posted
- 2022-12-22
- Last updated
- 2026-03-20
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05661955. Inclusion in this directory is not an endorsement.